30 June 2022
Vidi Grants awarded to Miao-Ping Chien, Rebekka Schneider, Tineke Lenstra and Monique Mulder
Oncode Institute is proud to announce that three Oncode Investigators and one Oncode Researcher will receive a Vidi Grant worth 800.000 euros. This grant will enable Oncode Investigators Miao-Ping Chien, Rebekka Schneider (both Erasmus MC), Tineke Lenstra (Netherlands Cancer Institute) and Oncode Researcher Monique Mulder (Leiden UMC) to develop their own innovative line of research and set up their own research group in the coming five years.
27 June 2022
Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. Oncode Investigator Wilbert Zwart and others publish about this discovery in cancer discovery today.
21 June 2022
Cell-free DNA biomarkers can help to identify treatment responders and non-responders of head and neck cancer patients
The team of Jeroen de Ridder finalized a Clinical Proof of Concept (CPoC) study in which they tested the feasibility of circulating tumor DNA (ctDNA) analysis in head- and neck cancer patients as treatment response identifier. Their results are promising and more extensive validation in larger patient cohorts is underway.
10 May 2022
Cancer Research UK forms strategic alliance with Oncode Institute
Cancer Research UK, the world’s largest private funder of cancer research, today announces a strategic alliance with Oncode Institute. The five-year partnership is the first under Cancer Research UK’s new innovation organisation, Cancer Research Horizons, as well as being Oncode’s first UK partner. The alliance aims to foster innovation and collaboration between world-leading cancer researchers.
In the spotlight
25 April 2022
Interview on Oncode-PACT: De-risking the preclinical phase
Although Dutch fundamental cancer research is among the world’s best, findings in this area rarely result in viable cancer medicines. How should this be improved? Oncode’s Managing Director Alain Kummer, Oncode Business Development expert Emil Pot and Friso Smit, business development manager of the Utrecht Science Park, reflect on this issue, with reference to the Oncode-PACT* Growth Fund proposal. They co-created this proposal with many other stakeholders.
6 May 2022
A new critical regulator of interferon signaling discovered
The group of Oncode Investigator Daniel Peeper (NKI) has published in Nature Communications its discovery of a new regulator of interferon γ (IFNγ signaling. The IFNγ response pathway is associated with response to immunotherapy in cancer.
4 May 2022
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
29 April 2022
Missing enzyme identified: how MATCAP works and affects brain development
Oncode Investigator Thijn Brummelkamp’s lab (NKI) previously identified Vasohibins as detyrosinating enzymes, but most cells contain detyrosinated microtubules even when the two Vasohibin genes are deleted. The team now identified MATCAP as a new enzyme involved in this process. Together with Oncode Investigator Anastassis Perrakis’ lab (NKI) they then showed how MATCAP works and how it engages with microtubules.
Scroll for more